Source-grounded facts extracted from ClearPoint Neuro, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ClearPoint Neuro, Inc. shareholders approved Approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan.
“The stockholders approved the Company's Seventh Amended and Restated 2013 Incentive Compensation Plan. The votes were cast as follows: For Against Abstentions Broker Non-Votes 7,517,634 1,793,261 495,788 9,991,790”
ClearPoint Neuro, Inc. shareholders approved Advisory approval of executive compensation.
“The stockholders, on an advisory basis, approved the compensation of the Company's executives. The votes were cast as follows: For Against Abstentions Broker Non-Votes 8,825,126 442,728 538,829 9,991,790”
ClearPoint Neuro, Inc. shareholders approved Ratification of the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm at the 2026-12-31 meeting.
“The stockholders ratified the selection of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: For Against Abstentions Broker Non-Votes 19,296,330 20,086 482,057 0”
ClearPoint Neuro, Inc. shareholders approved Election of seven directors to serve until the 2027 annual meeting.
“The following named persons were elected as directors of the Company to serve until the 2027 annual meeting of stockholders or until their successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. The votes were cast as follows: Name For Withheld Broker Non-Votes Joseph M. Burnett 9,686,224 120,459 9,991,790 Lynnette C. Fallon 9,625,049 181,634 9,991,790 R. John Fletcher 9,676,332 130,351 9,991,790 B. Kristine Johnson 9,628,069 178,614 9,991,790 Matthew B. Klein 9,639,952 166,731 9,991,790 Linda M. Liau 9,601,872 204,811 9,991,790 Timothy T. Richards 9,639,577 167,106 9,991,790”
ClearPoint Neuro, Inc. reported first fiscal quarter ended March 31, 2026 results: revenue $12.1 million. Guidance reaffirmed.
“to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Highlights • Reported first quarter revenue of $12.1 million, including $2.3 million of IRRA flow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025; • The activated”
ClearPoint Neuro, Inc. reported 2026 results: revenue $52.0 - $56.0 million. Guidance initiated.
“For 2026, we now expect revenues to be in the range of $52.0 - $56.0 million.”
ClearPoint Neuro, Inc. reported year ended December 31, 2025 results: revenue $37.0 million. Guidance reaffirmed.
“Reported revenue of $37.0 million for the full year 2025, an overall increase of 18% and 14% increase in organic growth over 2024 and signifying the eleventh consecutive year of growth”
ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $10.4 million. Guidance reaffirmed.
“Reported fourth quarter revenue of $10.4 million, including $1.2 million of IRRA flow revenue, representing 34% overall growth and 19% year-over-year organic growth compared with the fourth quarter of 2024”
ClearPoint Neuro, Inc. amended Consent to Note Purchase Agreement with CALW SA LLC (as Purchaser Agent) and TPC Investments III LP (affiliate of Oberland Capital Management LLC) valued at Consent to allow internal reorganization of Swedish subsidiary and qualify IRRAS AB as an Immaterial (effective 2025-12-29).
“On December 29, 2025, the Company entered into a Consent (the “Consent”) with Purchaser Agent and the 2025 Investor providing for the Company to undertake the following actions no later than January 15, 2026: (i) an internal reorganization involving the Company’s Swedish subsidiary, IRRAS AB, including the transfer of all equity interests of IRRAS USA, Inc. owned by IRRAS AB to the Company or its direct, wholly owned U.S. subsidiary in exchange for a subordinated intercompany note, and (ii) other further actions so as to allow IRRAS AB to qualify as an “Immaterial Foreign Subsidiary” under the terms of the Note Purchase Agreement.”
ClearPoint Neuro, Inc. completed an acquisition involving IRRAS Holdings, Inc. for $5,000,000 in cash and 1,325,000 shares of Company common stock (closed 2025-11-20).
“the “Merger”), with the Second Merger Sub surviving the Second Merger. Merger Consideration Pursuant to the Merger Agreement, the Company delivered closing consideration of $5,000,000 in cash and 1,325,000 shares of Company common stock to IRRAS shareholders (the “Closing Shares”). Earnout Consideration As additional consideration for IRRAS’ stockholders, the”
ClearPoint Neuro, Inc. shareholders approved Approval of the Fifth Amended and Restated 2013 Incentive Compensation Plan.
“Approval of the Fifth Amended and Restated 2013 Incentive Compensation Plan. The stockholders approved the Company’s Fifth Amended and Restated 2013 Incentive Compensation Plan. The votes were cast as follows: For Against Abstentions Broker Non-Votes 11,045,314 699,499 443,386 6,843,085”
ClearPoint Neuro, Inc. shareholders approved Advisory approval of executive compensation.
“Advisory approval of executive compensation. The stockholders, on an advisory basis, approved the compensation of the Company’s executives. The votes were cast as follows: For Against Abstentions Broker Non-Votes 11,126,888 629,515 431,796 6,843,085”
ClearPoint Neuro, Inc. shareholders approved Ratification of Cherry Bekaert LLP as independent registered public accounting firm for 2024 at the 2024-12-31 meeting.
“Ratification of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The votes were cast as follows: For Against Abstentions Broker Non-Votes 18,941,669 68,614 21,001 —”
ClearPoint Neuro, Inc. shareholders approved Election of eight directors to serve until the 2025 annual meeting.
“Election of Directors. The following named persons were elected as directors of the Company to serve until the 2025 annual meeting of stockholders or until their successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. The votes were cast as follows: Name For Withheld Broker Non-Votes Joseph M. Burnett 12,037,171 151,028 6,843,085 R. John Fletcher 11,734,172 454,027 6,843,085 Lynnette C. Fallon 11,780,550 407,649 6,843,085 Pascal E.R. Girin 11,771,794 416,405 6,843,085 B. Kristine Johnson 11,730,889 457,310 6,843,085 Matthew B. Klein 11,850,463 337,736 6,843,085 Linda M. Liau 11,716,020 472,179 6,843,085 Timothy T. Richards 11,625,429 562,770 6,843,085”
ClearPoint Neuro, Inc. reported the first quarter ended March 31, 2024 results: revenue $7.6 million. Guidance reaffirmed.
“precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights • Reported quarterly revenue of $7.6 million, a 41% year-over-year increase; • Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase; • Partner PTC Therapeutics submitted first-ever”
ClearPoint Neuro, Inc. reported the fiscal year ended December 31, 2023 results: revenue $24.0 million. Guidance reaffirmed.
“Reported revenue of $24.0 million for the full year 2023”
ClearPoint Neuro, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $6.8 million. Guidance reaffirmed.
“Reported fourth quarter 2023 revenue of $6.8 million”
ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $6.8 million.
“a Form 10-K filing for the year with full financial statements. Fourth Quarter 2023 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of approximately $6.8 million, a 32% year-over-year increase; • Increased biologics and drug delivery revenue to approximately $4.1 million, a 76% year-over-year increase; and • Cash burn of approximately”
ClearPoint Neuro, Inc. reported third quarter ended September 30, 2023 results: revenue $5.8 million, net income ($0.34) per diluted share, EPS ($0.34) per diluted share. Guidance reaffirmed.
“navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights • Reported quarterly revenue of $5.8 million, a 12% year-over-year increase; • Increased biologics and drug delivery revenue to $3.5 million, a 55% year-over-year increase; • Operational cash burn of $1.8 million, the”
ClearPoint Neuro, Inc. reported second quarter ended June 30, 2023 results: revenue record quarterly revenue of $6.0 million. Guidance reaffirmed.
“and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights • Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase; • Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase; • Announced an example of a milestone-based”
ClearPoint Neuro, Inc. amended Third Omnibus Amendment with PTC Therapeutics, Inc. and Petrichor Opportunities Fund I LP (effective 2023-07-31).
“On July 31, 2023, ClearPoint Neuro, Inc. (the “Company”), entered into a Third Omnibus Amendment (the “Amendment”) with PTC Therapeutics, Inc. (“PTC”), and Petrichor Opportunities Fund I LP, as collateral agent (“Petrichor,” and together with PTC, the “Investors”) to the Security Purchase Agreement, dated as of January 11, 2020, by and among the Company, the Investors, and Petrichor as collateral agent, as amended, (collectively with the Amendment, the “SPA”) to, among other things, (i) appoint PTC as the successor collateral agent, and (ii) replace the London Interbank Offered Rate (“LIBOR”) and LIBOR-based mechanics with an interest rate benchmark based on the Secured Overnight Financing Rate (“SOFR”) and related SOFR-based mechanics.”
ClearPoint Neuro, Inc.: Amendment to reduce authorized common shares from 200,000,000 to 90,000,000 (effective 2023-05-24).
“the Company’s stockholders approved an amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of the Company’s common stock from two hundred million (200,000,000) shares to ninety million (90,000,000) shares.”
ClearPoint Neuro, Inc. shareholders approved Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation.
“4. Approval of the Amendment to the Amended and Restated Certificate of Incorporation. The stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation. The votes were cast as follows: For Against Abstentions Broker Non-Votes 14,331,081 14,944 84,986 —”
ClearPoint Neuro, Inc. shareholders approved Advisory approval of executive compensation.
“3. Advisory approval of executive compensation. The stockholders, on an advisory basis, approved the compensation of the Company’s executives. The votes were cast as follows: For Against Abstentions Broker Non-Votes 9,224,361 127,029 223,249 4,856,372”
ClearPoint Neuro, Inc. shareholders approved Ratification of the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-12-31 meeting.
“2. Ratification of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The votes were cast as follows: For Against Abstentions Broker Non-Votes 14,419,693 3,150 8,168 —”
ClearPoint Neuro, Inc. shareholders approved Election of eight directors to serve until the 2024 annual meeting of stockholders.
“1. Election of Directors. The following named persons were elected as directors of the Company to serve until the 2024 annual meeting of stockholders or until their successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. The votes were cast as follows: Name For Withheld Broker Non-Votes Joseph M. Burnett 9,508,775 65,864 4,856,372 R. John Fletcher 8,847,706 726,933 4,856,372 Lynnette C. Fallon 8,767,508 807,131 4,856,372 Pascal E.R. Girin 8,847,611 727,028 4,856,372 B. Kristine Johnson 8,784,039 790,600 4,856,372 Matthew B. Klein 9,508,771 65,868 4,856,372 Linda M. Liau 9,504,476 70,163 4,856,372 Timothy T. Richards 8,848,151 726,488 4,856,372”
ClearPoint Neuro, Inc. reported first quarter ended March 31, 2023 results: revenue $5.4 million. Guidance reaffirmed.
“navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter Highlights • Reported quarterly revenue of $5.4 million, a 8% year-over-year increase; • Increased biologics and drug delivery revenue to $2.7 million, a 24% year-over-year increase; • Announced exclusive multi-year licensing”
ClearPoint Neuro, Inc. reported the year ended December 31, 2022 results: revenue $20.6 million. Guidance reaffirmed.
“Total revenue was $20.6 million and $16.3 million for the years ended December 31, 2022 and 2021, respectively.”
ClearPoint Neuro, Inc. reported the three months ended December 31, 2022 results: revenue $5.2 million.
“Total revenue was $5.2 million for the three months ended December 31, 2022, and $4.3 million for the three months ended December 31, 2021, which represents an increase of $0.9 million, or 21%.”
ClearPoint Neuro, Inc. reported full year ended December 31, 2022 results: revenue $20.6 million. Guidance initiated.
“cash equivalents, and short-term investments at December 31, 2022. Full Year 2022 Preliminary Unaudited Financial Highlights • Achieved preliminary unaudited record revenue of $20.6 million, a 26% year-over-year increase, versus most recent guidance of $21.0 - $22.0 million; • Increased biologics and drug delivery revenue to $9.1 million, a 34% year-over-year”
ClearPoint Neuro, Inc. reported the fourth fiscal quarter ended December 31, 2022 results: revenue $5.2 million.
“financial results for its fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of $5.2 million, a 21% year-over-year increase; • Increased biologics and drug delivery revenue to $2.3 million, a 37% year-over-year increase; • Increased functional neurosurgery products and”
ClearPoint Neuro, Inc.: Board adopted Fourth Amended and Restated Bylaws to enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, including compliance with Rule 14a-19 and changes to advance notice deadlines (effective 2022-12-14).
“Effective as of December 14, 2022, the Board of Directors of ClearPoint Neuro, Inc. (the “Company”) adopted the Fourth Amended and Restated Bylaws in connection with the new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the General Corporation Law of the State of Delaware, and a periodic review of the bylaws.”
ClearPoint Neuro, Inc. reported third quarter ended September 30, 2022 results: revenue $5.1 million. Guidance reaffirmed.
“navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022. Third Quarter Highlights • Reported quarterly revenue of $5.1 million, a 13% year-over-year increase; • Partner PTC Therapeutics’ gene therapy treatment Upstaza TM was granted full marketing authorization by the European Commission. Upstaza will be”
ClearPoint Neuro, Inc. entered into Lease Agreement with Hedda Marosi Living Trust and the Stella Feder Trust valued at $36,977.80 per month (effective 2022-11-04).
“On November 4, 2022, ClearPoint Neuro, Inc. (“Company”), entered into a lease agreement (the “Lease Agreement”) with the Hedda Marosi Living Trust and the Stella Feder Trust (collectively, the “Lessor”), pursuant to which the Lessor leases to the Company an approximately 19,462 square foot industrial building located at 6349 Paseo Del Lago, Carlsbad, CA 92011 (the “Leased Premises”).”
Mazin Sabra was appointed as Chief Operating Officer at ClearPoint Neuro, Inc..
“Mr. Sabra will join the Company as Chief Operating Officer, commencing on October 10, 2022”
Peter G. Piferi resigned as Chief Operating Officer at ClearPoint Neuro, Inc..
“Peter G. Piferi voluntarily resigned from his position as the Chief Operating Officer of ClearPoint Neuro, Inc. (the “Company”) and is separating from the Company, effective as of February 18, 2022”
Linda M. Liau was appointed as Director at ClearPoint Neuro, Inc..
“On November 2, 2021, the Board of Directors (the “ Board ”) of ClearPoint Neuro, Inc. (the “ Company ”) increased the size of the Board from seven to eight members, and, with the recommendation of the Corporate Governance and Nominating Committee of the Board, appointed Linda M. Liau, MD, PhD, MBA to fill the newly created directorship, effective immediately.”
Lynnette C. Fallon was appointed as Director at ClearPoint Neuro, Inc..
“appointed Lynnette C. Fallon to fill the newly created directorship, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.